Refine by
Disease Process Articles & Analysis
33 news found
As the field of genomics continues to evolve, long non-coding RNAs (lncRNAs) have emerged as a fascinating frontier, offering unprecedented insights into the complex regulatory mechanisms underlying biological processes and disease states. CD Genomics, a leading provider of high-throughput sequencing services, is at the forefront of this exciting development, ...
Small molecule drugs have a proven track record of success in treating a wide range of diseases, including cancer, cardiovascular disorders, and infectious diseases. By leveraging the potential of small molecules, our clients can benefit from: Targeted Therapies - Small molecules can be designed to selectively modulate specific biological targets, allowing for ...
Investigation of Complex Genomic Regions: LAA empowers scientists to delve into complex genomic regions that hold critical biological insights, such as regulatory elements, disease-related genes, and repetitive sequences. 3. Targeted Gene Analysis: Offering an economical and efficient solution for targeted gene analysis, LAA proves ideal for studying specific regions of ...
Cellworks Personalized Therapy Biosimulation The Cellworks Platform biosimulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and can also identify novel drug combinations for treatment-refractory patients. The platform is powered by the groundbreaking Cellworks CBM, a highly curated mechanistic network of 6,000+ human genes, ...
” Cellworks Therapy Biosimulation The Cellworks Platform biosimulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and can also identify novel drug combinations for treatment-refractory patients. The platform is powered by the groundbreaking Cellworks Computational Biology Model (CBM), a highly curated mechanistic network ...
These interactions affect fundamental processes and as a result, relevant protein DNA/RNA processing complexes and their associated mechanisms provide interesting therapeutic targets to researchers. ...
Cellworks Biosimulation Platform The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment. The platform is powered by Cellworks groundbreaking Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the ...
“The myCare-203A study shows us that the Cellworks Biosimulation Platform and SingulaTM TRI can streamline the treatment decision-making process and improve NSCLC patient outcomes through personalized therapy response ...
” The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. The platform is powered by the groundbreaking Cellworks Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species ...
“Using Cellworks SingulaTM TRI, we can simulate the molecular effects of cell signaling, drugs and radiation on patient-specific in silico diseased cells prior to treatment and then identify the magnitude of disease control and survival for specific anti-tumor strategies. ...
Eleven SAEs were related to the underlying disease process or other causes. The other six SAEs which occurred in four subjects were judged to be related to the administration procedure, with none of those being unexpected nor resulting in patient death. ...
” “Most urologists follow NCCN prostate cancer guidelines as a standard in the diagnosis and treatment of the disease,” said Mark Stovsky, M.D., Chief Medical Officer at Cleveland Diagnostics. ...
The investment will broaden the global patient reach of Mika, a personalized platform delivering evidence-based digital interventions to help cancer patients to better cope with the challenges of the disease and treatment process. The app combines AI-powered monitoring to track distress levels and symptoms along with a coaching section providing access to needed ...
ET- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results for the fourth quarter and full year 2021 and provided a corporate update. ...
The Company’s Solvent Interaction Analysis™ (SIA) technology investigates protein biomarkers at the structural level (as opposed to mere biomarker concentration) in blood, providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease process. Its portfolio of ...
AcuPebble SA100 is clinically equivalent to cardiorespiratory polygraphy for the automated diagnosis of obstructive sleep apnea (OSA) at home, a paper published in the BMJ Open has revealed. A powered clinical trial conducted by the Royal Free Hospital in London demonstrated both the accuracy and usability of the small device, which has the potential to open more efficient patient pathways for ...
AcuPebble SA100, a small wearable device that enables automated, remote home testing to detect obstructive sleep apnoea (OSA) in adults, has obtained FDA 510(k) clearance as a Class II medical device in the USA. The device, which received a CE Mark as a Class IIa medical device in 2020, was developed and is commercialised by UK-based medical device company Acurable and builds on more than ten ...
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...
“By combining Horizon’s expertise in gout with HemoShear’s REVEAL-TxTM drug discovery platform, we are managing a research program that has generated new insights into the disease process, identified novel gout targets and generated several first-in-class modulators of these ...
Reducing the number of unnecessary biopsies, increasing biopsy yield, and distinguishing high grade disease risk from low grade or benign disease with an effective blood test will be critical to savings lives, costs, and significantly improve overall patient ...